Cifras calculadas a partir de notificaciones regulatorias oficiales — .
Analistasobjetivo 4.03 USD (-75%)
Propiedadiniciados 0% · instituciones 47.23% · posiciones cortas 0.6% del flotante
En USD · a Oct 5, 2026
Pregúntale a la máquina
Busca y compara operaciones de iniciados, sociedades y sus estadísticas en lenguaje natural. Tu pregunta se convierte en una consulta sobre los datos disponibles, no en una conversación ni en asesoramiento de inversión.
Solo datos de Burning Rock Biotech Ltd. Sin búsqueda web. Se excluyen las estadísticas globales de cada iniciado.
Una búsqueda ejecutada consume un crédito, incluso sin resultados. Los errores y las preguntas no compatibles no consumen créditos.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Fuente de información de mercado · Oct 5, 2026
Identidad según la SEC · Oct 5, 2026
Cronología en el mercado · historial completo
8 compras— precio de cierrebarra = volumen usd, escala √haz clic en un periodo para filtrar la tabla
| Iniciado | Tipo | Valor · USD | Señales | Detalle |
|---|---|---|---|---|
| Han Yushenghistorial | Compra | $216.4K | conv 45 |
| SEC |
| Han Yushenghistorial | Compra | $44.9K | conv 32 | SEC |
| Han Yushenghistorial | Compra | $779.7K | conv 33 | SEC |
| Han Yushenghistorial | Compra | $2M | conv 34 | SEC |
| Han Yushenghistorial | Compra | $1M | conv 33 | SEC |
| Han Yushenghistorial | Compra | $1.9M | conv 43 | SEC |
| Han Yushenghistorial | Compra | $199.1K | conv 32 | SEC |
| Han Yushenghistorial | Compra | $5.5M | conv 51Primera en 12 meses | SEC |